Robert A. Blake
Impact in
- Molecular Biology top 2%
- Protein Degradation and Inhibitors
- Angiogenesis and VEGF in Cancer
- Protein Kinase Regulation and GTPase Signaling
- Ubiquitin and proteasome pathways
- Wnt/β-catenin signaling in development and cancer
-
- Renal cell carcinoma treatment
Papers in
-
- Protein Degradation and Inhibitors 12
- Protein Kinase Regulation and GTPase Signaling 5
- Heat shock proteins research 2
- Genetics 8
- Estrogen and related hormone effects 8
- Co-authors
- Sara A. Courtneidge (2 shared papers)Martin A. Broome (2 shared papers)Li Sun (2 shared papers)Jianming Wu (1 shared paper)Mikhail L. Gishizky (1 shared paper)Xiangdong Liu (1 shared paper)Steve P. Watson (3 shared papers)Emily Chan (2 shared papers)
- Journals
- Journal of Medicinal Chemistry (6 papers)Bioorganic & Medicinal Chemistry Letters (5 papers)Nature Communications (2 papers)ACS Medicinal Chemistry Letters (2 papers)FEBS Letters (2 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Robert A. Blake
37 papers receiving 5.2k citations
Robert A. Blake's Hit Papers
Peers
Comparison fields: 5 of 101
- Molecular Biology 2.4k
- Pulmonary and Respiratory Medicine 874
- Oncology 468
- Hepatology 160
- Pathology and Forensic Medicine 308
Countries citing papers authored by Robert A. Blake
This map shows the geographic impact of Robert A. Blake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Blake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Blake more than expected).
Fields of papers citing papers by Robert A. Blake
This network shows the impact of papers produced by Robert A. Blake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Blake. The network helps show where Robert A. Blake may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert A. Blake, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Hit paper breakdown → | 2003 | 1742 |
| 2 | 2000 | 533 | |
| 3 | A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. | 2003 | 449 |
| 4 | 2013 | 283 | |
| 5 | 2017 | 281 | |
| 6 | 2013 | 240 | |
| 7 | 2019 | 180 | |
| 8 | 2019 | 160 | |
| 9 | 2021 | 142 | |
| 10 | 2021 | 130 | |
| 11 | 1994 | 120 | |
| 12 | 2016 | 111 | |
| 13 | 2021 | 106 | |
| 14 | 2019 | 104 | |
| 15 | Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. | 2003 | 97 |
| 16 | Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. | 2003 | 96 |
| 17 | Src promotes PKCdelta degradation. | 1999 | 88 |
| 18 | 2022 | 81 | |
| 19 | 2017 | 75 | |
| 20 | 2020 | 52 |
About Robert A. Blake
Robert A. Blake is a scholar working on Molecular Biology, Genetics, Hematology, Computational Theory and Mathematics and Pathology and Forensic Medicine, having authored 38 papers that have together received 5.3k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (12 papers), Estrogen and related hormone effects (8 papers), Protein Kinase Regulation and GTPase Signaling (5 papers), Platelet Disorders and Treatments (3 papers), Cancer Mechanisms and Therapy (3 papers), Computational Drug Discovery Methods (3 papers), Heat shock proteins research (2 papers) and Liver physiology and pathology (2 papers). The work is most often cited by research in Molecular Biology (2.4k citations), Pulmonary and Respiratory Medicine (874 citations), Oncology (468 citations), Hepatology (160 citations) and Pathology and Forensic Medicine (308 citations). Robert A. Blake has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Sara A. Courtneidge, Martin A. Broome, Li Sun, Jianming Wu, Mikhail L. Gishizky, Xiangdong Liu, Steve P. Watson, Emily Chan, Julie M. Cherrington and Dirk B. Mendel. Their work appears in journals such as Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, Nature Communications, ACS Medicinal Chemistry Letters and FEBS Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.